Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management

Phase 3ASC30Positive

AI Analysis

Summary

Ascletis announced the first participant dosed in a global Phase III program (AURORA-1 and AURORA-2) evaluating ASC30, a once-daily oral GLP-1 receptor agonist, for chronic weight management in approximately 4,600 participants across the U.S., Europe, and Canada.

Clinical Trial Data

Phase

Phase 3

Patients

4,600

Outcome Details

First participant dosed in global Phase III program

Importance:6/10

Sentiment:

0.50

Phase 3GLP-1 receptor agonistobesityweight managementoral small moleculeAURORA-1AURORA-2

Related Companies

$GBCYD $TRAX

Read the original article

Published by PR Newswire Clinical Trials on August 30, 2026 10:15 AM

Read Original